Levomethadone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Levomethadone

Examples of brand names: L-Polamidon [DE]

ATC code: N07BC05

Main use (for orientation): Opioid dependence

Documented research summary

German product information explicitly names cannabidiol. A regulatory warning, not a controlled levomethadone–CBD pharmacokinetic experiment identified here; racemic methadone remains separate.

Uncertainties and limitations

Regulatory warning without a CBD dose or numerical effect in the SmPC. Several CYP pathways, no isolated proven mechanism. Local product information from May 2026 replaces an earlier date note of April 2026.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Theoretical context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Theoretical plausibility; no verified clinical pair effect

Mechanism / drug context: Levomethadone: specific product-information warning about possible increased concentrations with CBD.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Levomethadone hydrochloride, Aristo oral tablets; R(−)-enantiomer, not racemic methadone; active ingredient.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0145]: Regulatory warning

Statement supported: Product information mentions a possible rise in levomethadone concentrations with CBD, not a dedicated controlled experiment with the pair.

Source: Levomethadon Aristo 2,5/5/7,5/20/30 mg Tabletten – Fachinformation [CA_L_D0145]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0145] Levomethadon Aristo 2,5/5/7,5/20/30 mg Tabletten – Fachinformation

Original source / bibliographic reference

Authors: Aristo Pharma GmbH

Year: 2026

Source type: Manufacturer's product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_39849214] Drug interactions in a sample of inpatients diagnosed with cannabis use disorder.

Original source / bibliographic reference

Authors: Schulze Westhoff M, Massarou C, Bleich S, Heck J, Jendretzky KF, Glahn A, Schröder S.

Year: 2025

Source type: Research Support, Non-U.S. Gov't; research-article; Journal Article

DOI: 10.1007/s00702-025-02884-5

PMID: 39849214

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_35214192] Multicenter Observational/Exploratory Study Addressed to the Evaluation of the Effectiveness and Safety of Pharmacological Therapy in Opioid-Dependent Patients in Maintenance Therapy in Southern Italy.

Original source / bibliographic reference

Authors: Maqoud F, Fabio G, Ciliero N, Antonacci M, Mastrangelo F, Sammarruco G, Cataldini R, Schirosi G, De Fazio S, Tricarico D.

Year: 2022

Source type: research-article; Journal Article

DOI: 10.3390/pharmaceutics14020461

PMID: 35214192

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility